Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 5/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | ESRRB | O95718 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918691 | 0.95 | GSK3B (0.55) | GSK3BPOLA1SYKAKR1B10AKR1B1 | |
| SCHEMBL6080527 | 0.91 | CA1 (0.52) | GSK3BPOLA1 | |
| SCHEMBL1919137 | 0.89 | POLA1 (0.59) | POLA1SYKAKR1B10AKR1B1ESRRB | |
| SCHEMBL6080767 | 0.86 | GSK3B (0.47) | GSK3BPOLA1SYKAKR1B10AKR1B1 | |
| SCHEMBL1919215 | 0.82 | POLA1 (0.47) | GSK3BPOLA1SYKAKR1B10AKR1B1 | |
| SCHEMBL1917291 | 0.82 | KDM1A (0.60) | GSK3BPOLA1AKR1B10AKR1B1 | |
| SCHEMBL1918021 | 0.81 | CA1 (0.57) | POLA1AKR1B10AKR1B1 | |
| SCHEMBL1919226 | 0.80 | SYK (0.51) | GSK3BPOLA1SYKAKR1B10AKR1B1 | |
| SCHEMBL1918211 | 0.80 | SYK (0.56) | GSK3BPOLA1SYKAKR1B10AKR1B1 | |
| SCHEMBL1917801 | 0.80 | GSK3B (0.53) | GSK3BPOLA1SYKAKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154933-A1 | Inhibitors of Cdc25 phosphatases | SCRAS | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154933-A1 | Inhibitors of Cdc25 phosphatases | CDC25A, CDC25C, CDC25B | GSK3B 491/4885POLA1 1114/4885SYK 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.